Zobrazeno 1 - 10
of 133
pro vyhledávání: '"Pansclerotic Morphea"'
Publikováno v:
Вопросы современной педиатрии, Vol 19, Iss 2, Pp 150-161 (2020)
The localized scleroderma (morphea) is the clinical option of the juvenile scleroderma, the third in prevalence rheumatic condition in pediatrics. The article summarizes all the data on the classification, diagnostics, and differential diagnosis of j
Externí odkaz:
https://doaj.org/article/30c3d1c64e6e4c4ca72d45f2ada98396
Autor:
Zahra Lotfi, Anousheh Haghighi, Amirhossein Akbarzadehpasha, Samaneh Mozafarpoor, Azadeh Goodarzi
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
While mucocutaneous manifestations of COVID-19 have been frequently reported and added to our knowledge every day during the pandemic, another issue is the COVID-related diseases that can present as intensified lesions of underlying diseases, a new d
Externí odkaz:
https://doaj.org/article/0aaa2be9997948bea6db89f9aee906a4
Autor:
Sarah Ventéjou, Agnes Schwieger-Briel, Rebecca Nicolai, Stephanie Christen-Zaech, Caroline Schnider, Michael Hofer, Sofia Bogiatzi, Daniel Hohl, Fabrizio De Benedetti, Marie-Anne Morren
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Pansclerotic morphea (PSM) is a rare skin disease characterized by progressive stiffening of the skin with or without the typical superficial skin changes usually seen in morphea (localized scleroderma). Standard therapy, consisting of a combination
Externí odkaz:
https://doaj.org/article/2252460042a94d19be8d3a5d47b5abf2
Autor:
Giorgia Martini, Laura Saggioro, Francesco Zulian, Alessandra Meneghel, Roberta Culpo, Fabio Vittadello
Publikováno v:
Rheumatology (Oxford, England)
ObjectivesTo investigate safety and efficacy of MMF in patients with severe or MTX-refractory juvenile localized scleroderma.MethodsConsecutive juvenile localized scleroderma patients undergoing systemic treatment were included in a retrospective lon
Publikováno v:
Indian Dermatology Online Journal, Vol 5, Iss 2, Pp 170-172 (2014)
Morphea is a variant of localized scleroderma in which lesions are usually limited to the skin and subcutaneous tissue. Pansclerotic morphea is a rare atrophying and sclerosing type of morphea. It can follow a comparatively benign course with spontan
Externí odkaz:
https://doaj.org/article/2e8bb7c93abe490c95a43e6778efd129
Autor:
Fabrizio De Benedetti, Rebecca Nicolai, Sofia Bogiatzi, Caroline Schnider, Agnes Schwieger-Briel, Michael Hofer, Stéphanie Christen-Zaech, Marie-Anne Morren, Daniel Hohl, Sarah Ventéjou
Publikováno v:
Frontiers in immunology, vol. 12, pp. 656407
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology
Pansclerotic morphea (PSM) is a rare skin disease characterized by progressive stiffening of the skin with or without the typical superficial skin changes usually seen in morphea (localized scleroderma). Standard therapy, consisting of a combination
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74dc39d97aa18c6bc0598ad82d8f8614
https://serval.unil.ch/resource/serval:BIB_F62DE0476303.P001/REF.pdf
https://serval.unil.ch/resource/serval:BIB_F62DE0476303.P001/REF.pdf
Publikováno v:
Rheumatology International. 39:933-941
Disabling pansclerotic morphea of childhood (DPMC) is a rare subtype of juvenile localized scleroderma (JLS) characterized by pansclerosis mainly affecting children under the age of 14. This aggressive disease has a poor prognosis due to the rapid pr
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
JAMA Dermatol
Importance Numerous classification systems for morphea subtypes exist, but none have been systematically evaluated for their ability to categorize patients with morphea into demographically and clinically coherent groups. Although some subtypes, such
Autor:
Francesca Tirelli, Francesco Zulian
Publikováno v:
Current rheumatology reports. 22(8)
Treatment of scleroderma in children is challenging since little is known about its pathogenesis. Herein, we review the most recent evidence regarding the treatment of juvenile scleroderma. According to the recent recommendations for Pediatric Rheuma